Pfizer (PFE) Cost of Revenue (2009 - 2026)

Pfizer (PFE) has 18 years of Cost of Revenue data on file, last reported at $3.5 billion in Q1 2026.

• Quarterly Cost of Revenue rose 24.71% year-over-year to $3.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.8 billion (up 13.41% YoY) and the FY2025 annual result came in at $16.1 billion, down 9.99% from the prior year.
• Cost of Revenue eased to $3.5 billion in Q1 2026 per PFE's latest filing, from $5.3 billion in the prior quarter.
• Across five years, Cost of Revenue topped out at $10.0 billion in Q2 2022 and bottomed at $2.8 billion in Q1 2025.
• The 5-year median for Cost of Revenue is $4.9 billion (2023), against an average of $5.4 billion.
• The widest annual swing landed in 2022, when Cost of Revenue surged 140.17%; it then tumbled 62.57% in 2023.
• Tracing PFE's Cost of Revenue over 5 years: stood at $6.1 billion in 2022, then advanced by 24.74% to $7.6 billion in 2023, then tumbled by 30.41% to $5.3 billion in 2024, then rose by 0.17% to $5.3 billion in 2025, then slumped by 32.7% to $3.5 billion in 2026.
• Per Business Quant, the three latest PFE Cost of Revenue figures stand at $3.5 billion (Q1 2026), $5.3 billion (Q4 2025), and $4.2 billion (Q3 2025).

Peer Comparison